CSL Behring
Clinical Trials
143
Trial Phases
5 Phases
Drug Approvals
32
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (120 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
- Conditions
- Complex Cardiovascular Surgery With Cardiopulmonary Bypass
- Interventions
- Biological: FFP
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 200
- Registration Number
- NCT07094087
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
- Conditions
- Hemophilia B
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 18
- Registration Number
- NCT07080905
- Locations
- 🇺🇸
University of Florida - 84000399, Gainesville, Florida, United States
🇺🇸University of Michigan Medical Center - 84000491, Ann Arbor, Michigan, United States
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
- Conditions
- Primary Immunodeficiency
- Interventions
- Biological: IgPro
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 8
- Registration Number
- NCT07076446
- Locations
- 🇺🇸
84000890 - Research Solutions of AZ, Litchfield Park, Arizona, United States
🇺🇸84000910 - Immunoe Health Centers, Centennial, Colorado, United States
🇺🇸84000918 - Midwest Immunology, Plymouth, Minnesota, United States
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
- Conditions
- Non-cystic Fibrosis Bronchiectasis
- Interventions
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 450
- Registration Number
- NCT07048262
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
- Conditions
- Hereditary Angioedemas
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 200
- Registration Number
- NCT07001280
- Locations
- 🇩🇪
Charite, Berlin, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 28
- Next
News
CSL Behring's Australian Plasma Facility Wins Global Manufacturing Excellence Award for Advanced Automation
CSL Behring's $900 million plasma fractionation facility in Broadmeadows, Victoria, has been named 2025 Facility of the Year in the Pharma 4.0 category by the International Society for Pharmaceutical Engineering.
Iovance Biotherapeutics Names Corleen Roche as CFO During Commercial Launch of First FDA-Approved TIL Therapy
Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy.
FDA Approves CSL's ANDEMBRY for Hereditary Angioedema Prevention with Novel Factor XIIa Targeting
The FDA approved ANDEMBRY (garadacimab-gxii), the first and only prophylactic HAE treatment targeting factor XIIa, offering once-monthly dosing for patients 12 years and older.
ISPE Celebrates 20th Anniversary with Announcement of 2025 Facility of the Year Awards Winners
Six pharmaceutical facilities received category awards for innovation, operations, and social impact at the 2025 ISPE Europe Annual Conference, marking the 20th anniversary of the prestigious FOYA program.
Injectable Drug Delivery Market Projected to Reach $1.14 Trillion by 2029 as Industry Leaders Convene for Innovation Summit
The injectable drug delivery market is projected to reach $1,139.4 billion by 2029, driven by complex biologics and increased demand for patient self-administration.
Non-Cystic Fibrosis Bronchiectasis Market Expected to Reach USD 7.5 Billion by 2035, Driven by Novel Therapies
The Non-Cystic Fibrosis Bronchiectasis (NCFB) market is projected to grow from USD 1.7 billion in 2024 to USD 7.5 billion by 2035, representing a robust CAGR of 14.62%.
Major Advances in Angioedema Pipeline: Intellia's Gene Therapy Enters Phase 3 as Multiple Companies Race for Novel Treatments
Intellia Therapeutics has initiated Phase 3 trials for NTLA-2002, a groundbreaking CRISPR-based gene therapy for hereditary angioedema, with potential U.S. launch targeted for 2027.
Pfizer Discontinues Beqvez Gene Therapy for Hemophilia B Amid Low Market Demand
Pfizer has announced the cessation of development and commercialization of Beqvez, its FDA-approved gene therapy for hemophilia B, citing limited interest from patients and healthcare providers.
Hemgenix Gene Therapy Shows Sustained Efficacy in Hemophilia B Patients After Four Years
Data from the HOPE-B trial demonstrates that Hemgenix (etranacogene dezaparvovec-drlb) provides long-term bleed protection for adults with hemophilia B.
Major Breakthroughs in HAE Treatment: 2024 Highlights Gene Editing and Novel Therapeutics
2024 marked significant advances in hereditary angioedema (HAE) treatment, with Intellia's gene-editing therapy NTLA-2002 showing a remarkable 95% reduction in monthly attacks. The year also saw important developments in multiple therapeutic candidates, including donidalorsen and garadacimab, while established treatments like Takhzyro demonstrated continued efficacy in adolescent populations.